Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699061 | 0.74 | ALDH1A1 (0.41) | ALDH1A1KDM4C | |
| SCHEMBL23458100 | 0.71 | ALDH1A1 (0.43) | ELANEALDH1A1CHRNB2CHRNA4CYP2E1 | |
| SCHEMBL23457989 | 0.71 | ELANE (0.36) | ELANECHRNB2CHRNA4CYP2E1CYP2A6 | |
| SCHEMBL23458065 | 0.71 | KMT2A (0.35) | ALDH1A1KCNJ1CYP2A6HDAC6 | |
| SCHEMBL21994698 | 0.70 | PREP (0.39) | ALDH1A1KDM4C | |
| SCHEMBL21978533 | 0.69 | NPC1 (0.49) | ALDH1A1PTGS2KCNH2HDAC6 | |
| SCHEMBL29768506 | 0.68 | NPC1 (0.44) | ALDH1A1 | |
| SCHEMBL23458339 | 0.68 | NPC1 (0.44) | ALDH1A1 | |
| SCHEMBL23458047 | 0.68 | ELANE (0.33) | ELANECHRNB2CHRNA4CYP2E1CYP2A6 | |
| SCHEMBL29768561 | 0.68 | ELANE (0.33) | ELANECHRNB2CHRNA4CYP2E1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-114746408-B | Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors | 豪夫迈·罗氏有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4069685-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20220306607-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-09-29 | — | — | US | disclosed |
| CN-114746408-A | Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021110574-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110574-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HCN1, HCN2, HCN3 | ELANE 2173/4885ALDH1A1 529/4885KDM4C 1560/4885 |
| US-20220306607-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | HCN1, HCN2, HCN3 | ELANE 3489/4885ALDH1A1 197/4885KDM4C 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.